Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy

被引：0
|
作者：
M. Kalder
I. Kyvernitakis
U. S. Albert
M. Baier-Ebert
P. Hadji
机构：
[1] Philipps University of Marburg,Department of Obstetrics and Gynecology
[2] Krankenhaus Nordwest,Department of Obstetrics and Gynecology
[3] Novartis Pharma GmbH,Clinical & Regulatory Affairs/Biometrics Department
[4] Krankenhaus Nordwest,Department of Bone Oncology, Endocrinology and Reproductive Medicine
来源：
Osteoporosis International | 2015年 / 26卷
关键词：
Bone mineral density; Breast cancer; Osteoporosis; Trabecular bone score; Zoledronic acid;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：353 / 360
页数：7
相关论文
共 50 条
  • [21] Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom
    Lester, JE
    Dodwell, D
    Horsman, JM
    Mori, S
    Coleman, RE
    BRITISH JOURNAL OF CANCER, 2006, 94 (01) : 30 - 35
  • [22] Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom
    J E Lester
    D Dodwell
    J M Horsman
    S Mori
    R E Coleman
    British Journal of Cancer, 2006, 94 : 30 - 35
  • [23] Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients
    Seung Ah Lee
    Seung Hyun Hwang
    Sung Gwe Ahn
    Hak Min Lee
    Joon Jeong
    Hy-De Lee
    Breast Cancer Research and Treatment, 2011, 130 : 863 - 870
  • [24] Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients
    Lee, Seung Ah
    Hwang, Seung Hyun
    Ahn, Sung Gwe
    Lee, Hak Min
    Jeong, Joon
    Lee, Hy-De
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 130 (03) : 863 - 870
  • [25] Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer
    Hershman, Dawn L.
    McMahon, Donald J.
    Crew, Katherine D.
    Cremers, Serge
    Irani, Dinaz
    Cucchiara, Gina
    Brafman, Lois
    Shane, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) : 4739 - 4745
  • [26] Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early stage breast cancer.
    Hershman D L
    McMahon D
    Crew K
    Cremers S
    Irani D
    Cucchiara G
    Brafman L
    Siarra A
    Shane E
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S38 - S38
  • [27] Bone mineral density loss in premenopausal women given adjuvant chemotherapy for early breast cancer is independant of effects on ovarian function
    Cameron, DA
    Douglas, S
    Creiger, J
    Anderson, RA
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S98 - S99
  • [28] Effect of zoledronic acid (ZA) versus placebo on bone mineral density (BMD) in androgen-deprived prostate cancer patients with and without bone metastases (mets).
    Ryan, CW
    Huo, D
    Hanson, M
    Stadler, WM
    Vogelzang, NJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 446S - 446S
  • [29] Not all patients with premenopausal breast cancer will experience the negative effects of tamoxifen treatment on their bone mineral density
    Altundag, Kadri
    BREAST CANCER, 2024, 31 (05) : 997 - 997
  • [30] Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer
    Tevaarwerk, A.
    Stewart, J. A.
    Love, R.
    Binkley, N. C.
    Black, S.
    Eickhoff, J.
    Mulkerin, D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345